HRTX · XBRL financial data

Heron Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HRTX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of goods and services sold	18	10*	8	11	9	10*	8	10	12	11*	11	12
Gross profit	13	—	26	26	23	—	30	27	26	—	24	26
Research and development	14	11*	5	4	4	3*	2	3	3	4*	2	3
General and administrative	12	11*	15	14	12	12*	13	14	14	13*	12	11
Operating income (loss)	(25)	(10)*	(5)	(6)	(4)	4*	3	(2)	(4)	0*	(5)	(2)
Interest income	—	year only	—	—	—	year only	—	—	—	year only	—	—
Interest expense	—	year only	—	—	—	year only	—	—	—	year only	—	—
Other income (expense)	(0)	0*	2	(3)	(0)	2*	(1)	(1)	(2)	5*	(3)	(3)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(25)	(11)*	(3)	(9)	(5)	4*	3	(2)	(17)	(3)*	(8)	(5)
Earnings per share, basic USD per share	(0.17)	(0.06)*	(0.02)	(0.06)	(0.03)	0.02*	0.02	(0.02)	(0.10)	(0.02)*	(0.04)	(0.03)
Earnings per share, diluted USD per share	(0.17)	(0.06)*	(0.02)	(0.06)	(0.03)	0.02*	0.01	(0.02)	(0.10)	(0.02)*	(0.04)	(0.03)
Weighted average shares, basic millions of shares	145	168*	151	152	153	153*	153	154	170	189*	190	190
Weighted average shares, diluted millions of shares	145	168*	151	152	153	153*	197	154	170	146*	190	190

Fiscal quarters (HRTX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	35	29	20	18	26	26	19	17	43	29	26	21
Marketable securities	43	52	51	49	45	33	31	24	12	18	19	22
Accounts receivable	64	60	65	74	67	79	79	80	81	90	84	90
Inventory	42	42	42	43	46	53	57	73	70	93	93	91
Prepaid and other current assets	11	6	7	7	11	18	26	17	23	9	8	7
Total current assets	194	189	186	191	195	209	213	211	229	238	229	230
Property and equipment, net	21	20	19	16	15	15	15	14	13	12	12	12
Right-of-use asset	6	5	5	4	3	3	2	1	1	0	—	6
Total assets	229	223	218	218	221	233	236	232	249	256	246	252
Accounts payable	2	3	1	10	10	12	12	12	12	9	9	12
Total current liabilities	80	80	75	80	86	91	89	259	90	96	91	92
Lease liability, non-current	4	3	2	1	1	—	—	—	—	0	—	6
Total liabilities	257	256	252	256	261	267	264	259	234	242	237	245
Accumulated deficit	(1,895)	(1,906)	(1,909)	(1,918)	(1,923)	(1,920)	(1,917)	(1,919)	(1,937)	(1,940)	(1,948)	(1,953)
Total stockholders' equity	(28)	(34)	(34)	(38)	(40)	(34)	(28)	(27)	15	14	9	7
Total liabilities and equity	229	223	218	218	221	233	236	232	249	256	246	252
Common shares outstanding (cover page) millions of shares	150	150	151	152	152	152	153	153	183	189	189	190

Fiscal quarters (HRTX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(25)	(11)*	(3)	(9)	(5)	4*	3	(2)	(17)	(3)*	(8)	(5)
Stock-based compensation	7*	4*	3	5*	3*	2*	3	3*	3*	2*	3	3*
Depreciation and amortization	1*	1*	1	1*	1*	1*	1	1*	1*	1*	1	0*
Net cash from operating activities	(9)*	2*	(10)	(5)*	3*	(12)*	(9)	(11)*	1*	(9)*	(2)	(2)*
Purchases of property and equipment	1*	0*	—	—	0*	1*	0	0*	0*	0*	0	0*
Net cash from investing activities	(23)*	(9)*	1	2*	4*	11*	2	7*	12*	(5)*	(1)	(3)*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	—	(2)*	—	—
Net cash from financing activities	54*	0*	0	0*	0*	0*	0	1*	13*	0*	(0)	0*
Net change in cash	21*	(6)*	(8)	(2)*	7*	0*	(7)	(3)*	27*	(14)*	(3)	(5)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Heron Therapeutics	21	not reported	(2.2)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199	not reported	(48)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17	not reported	(2.2)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	166	1.6	(52)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	19	not reported	(15)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16	55	(18)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.